Shares of Panacea Biotec rallied 8% on 15 December after the company announced the launch of its fully-liquid wP-IPV-based pentavalent vaccine named ‘EasyFourPol’ in India. 

In its regulatory filing, the company said that its step-down wholly-owned subsidiary has launched the world’s first fully-liquid wP-IPV-based Pentavalent vaccine, EasyFourPol, in India and registration of Valganciclovir 50 mg/ml Powder for Oral Solution. 

EasyFourPol is the world’s first fully-liquid wP-IPV Pentavalent vaccine that protects children against five deadly diseases, including Tetanus, Polio, Diphtheria, Pertussis, and invasive infections caused by Haemophilus Influenza Type b.

Panacea Biotec Germany GmbH, the company’s subsidiary in Germany, has received registration of Valganciclovir Powder, which is a deoxynucleoside analogue cytomegalovirus DNA polymerase inhibitor indicated;

1. The prophylaxis of CMV disease in CMV-negative adults and children (from birth and up to 18 years of age) who have received an organ transplant from a CMV-positive donor.
2. The initial and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS)

In October, Panacea Biotec Pharma Limited, a material wholly-owned subsidiary of the company through its strategic partner Apotex IncCanada lau,nched Paclitaxel protein-bound particles for injectable suspension (Albumin-Bound), which is a generic version of Abraxane in the Canadian market.

At 11:16 am, the shares of Panacea Biotec were trading 4.23% higher at Rs 169.95 on NSE.